Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.07 Insider Own61.32% Shs Outstand39.38M Perf Week21.68%
Market Cap374.65M Forward P/E- EPS next Y-1.39 Insider Trans0.00% Shs Float15.37M Perf Month44.85%
Income-35.48M PEG- EPS next Q-0.31 Inst Own47.07% Short Float / Ratio12.60% / 13.57 Perf Quarter56.91%
Sales0.00M P/S- EPS this Y57.63% Inst Trans- Short Interest1.94M Perf Half Y87.48%
Book/sh6.87 P/B1.37 EPS next Y-24.77% ROA-12.09% Target Price7.00 Perf Year-55.07%
Cash/sh6.89 P/C1.37 EPS next 5Y- ROE-12.42% 52W Range3.75 - 23.42 Perf YTD119.30%
Dividend- P/FCF- EPS past 5Y- ROI-12.84% 52W High-59.74% Beta3.26
Dividend %- Quick Ratio47.00 Sales past 5Y0.00% Gross Margin- 52W Low151.47% ATR0.66
Employees28 Current Ratio47.00 Sales Q/Q- Oper. Margin0.00% RSI (14)80.28 Volatility12.77% 7.58%
OptionableYes Debt/Eq0.02 EPS Q/Q11.44% Profit Margin- Rel Volume11.38 Prev Close9.50
ShortableYes LT Debt/Eq0.01 EarningsNov 09 BMO Payout- Avg Volume142.65K Price9.43
Recom2.00 SMA2033.16% SMA5038.54% SMA20069.20% Volume1,622,762 Change-0.74%
Date Action Analyst Rating Change Price Target Change
Dec-16-22Downgrade Jefferies Buy → Hold $30 → $3.60
Dec-15-22Downgrade Morgan Stanley Overweight → Equal-Weight $5
Oct-10-22Initiated Morgan Stanley Overweight $34
Oct-10-22Initiated Jefferies Buy $30
Oct-10-22Initiated Cowen Outperform
Nov-09-23 09:30AM
Oct-31-23 08:30AM
Aug-31-23 08:30AM
Aug-10-23 08:10AM
09:40AM Loading…
Jul-26-23 09:40AM
Jul-25-23 08:30AM
Jun-09-23 08:04AM
May-24-23 11:02AM
May-11-23 05:00PM
Mar-29-23 08:05AM
Dec-23-22 06:32AM
Dec-22-22 05:41AM
Dec-15-22 10:10AM
08:49AM Loading…
Nov-21-22 04:05PM
Nov-09-22 04:15PM
Nov-02-22 08:01AM
Sep-19-22 04:10PM
Sep-15-22 11:41AM
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/IL10% OwnerDec 20Buy4.11214,063879,4992,332,638Dec 22 06:49 PM